Radioactive drug targets Hard-to-Treat melanoma in early trial
NCT ID NCT07076550
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a radioactive drug called [225Ac]Ac-A9-3408 in 50 adults with melanoma that has spread or can't be removed by surgery. The main goals are to find a safe dose and check for side effects. Participants receive the drug every 6 weeks for up to 6 doses, and doctors will also see if tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A radioactive drug called [225Ac]Ac-A9-3408 given by IV
What this could lead to
If it works, this could point toward a new treatment option for advanced melanoma that has spread or cannot be removed by surgery.
What could go wrong
This is an early Phase 1 trial with only 50 people, so safety and effectiveness are not yet known. The drug is radioactive and may cause side effects; it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA, METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Health
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Austin Health
RECRUITINGMelbourne, Victoria, 3084, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fiona Stanley Hospital
NOT_YET_RECRUITINGMurdoch, Western Australia, 6150, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
GenesisCare Murdoch
NOT_YET_RECRUITINGMurdoch, Western Australia, 6150, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact